Oryzon Genomics S.A.   Report issue

For profit Phase 1 Phase 2
Founded: Barcelona Spain (2000)

Organization Overview

First Clinical Trial
2019
NCT03867253
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Oryzon Genomics | Oryzon Genomics S.A.

Active Ingredients

Drugs in Phase 2 Trials (3)

iadademstat (2 trials)

ory-2001 (2 trials)

paclitaxel (taxol) (1 trial)

Drugs in Phase 1 Trials (1)

gilteritinib (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 4